French Market Survives On New Generics
Greater Emphasis On Biosimilars Urged By Gemme As Uptake Stalls
After a year that French industry association Gemme says has demonstrated the importance of a sustainable generics sector, the market continued to grow purely due to the contribution made by newly genericized molecules.
You may also be interested in...
French off-patent industry association Gemme has declared a “state of emergency” for French generics as it revealed industry data for 2019 pointing to weak growth. Meanwhile, Gemme says, the country’s biosimilars market is “dynamic” and growing quickly but is still under-performing.
Agoal of 80% biosimilar penetration within their individual markets by 2022 has been set by France’s government, as part of a broader healthcare strategy set out by the health ministry for the next five years. This will be achieved by promoting biosimilars “which present the same efficacy, the same quality and the same safety as the biological reference product”, according to the proposals. Local medicines agency ANSM recently introduced 11 ‘similar biologic groups’ designating equivalence categories for biosimilars, alongside guidance that advises prescribing biosimilars at any point during a course of treatment and favours lowerpriced alternatives (Generics bulletin, 10 November 2017, page 11).
Hyloris is on a roll with licensing deals for its Maxigesic IV non-opioid pain treatment, with an extension of its existing agreement with Pharma Bavaria to cover South American territories coming hot on the heels of recent developments in the US and Europe.